{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:08:58Z","timestamp":1793239738643,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual stroke rate in patients with atrial fibrillation remains 1\u20132%. Rapid exclusion of relevant anticoagulation is necessary to guide thrombolysis or reversal therapy but, so far, no data exists on the effect of edoxaban on available point-of-care test systems (POCT). To complete our previous investigation on global coagulation-POCT for the detection of DOAC, we evaluated whether CoaguChek\u00ae-INR (CC-INR) is capable of safely ruling out edoxaban concentrations above the current treatment thresholds of 30\/50 ng\/mL in a blood sample. We studied patients receiving a first dose of edoxaban; excluding subjects receiving other anticoagulants. Six blood samples were collected from each patient: before drug intake, 0.5, 1, 2 and 8 h after intake, and at trough (24 h). CC-INR and mass spectrometry for edoxaban concentrations were performed for each time-point. One hundred and twenty blood samples from 20 patients contained 0\u2013302 ng\/mL of edoxaban. CC-INR ranged from 0.9 to 2.3. Pearson\u2019s correlation coefficient showed strong correlation between CC-INR and edoxaban concentrations (r\u2009=\u20090.73,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Edoxaban concentrations\u2009&gt;\u200930 and &gt;\u200950 ng\/mL were ruled out by CC-INR\u2009\u2264\u20091.0 and \u2264\u20091.1, respectively, with high specificity (&gt;\u200995%), and a sensitivity of 44% (95%-confidence interval: 30\u201359%) and 86% (74\u201393%), respectively. Our study represents the first evaluation of coagulation-POCT in edoxaban-treated patients. CC-POCT is suitable to safely exclude clinically relevant edoxaban concentrations prior to thrombolysis, or guide reversal therapy in stroke patients.\n                  <\/jats:p>","DOI":"10.1007\/s11239-020-02143-2","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T08:02:55Z","timestamp":1589961775000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Point-of-care testing of coagulation in patients treated with edoxaban"],"prefix":"10.1007","volume":"50","author":[{"given":"Florian","family":"H\u00e4rtig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Birschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"H\u00f6rber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Sonnleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Ioanna","family":"Stefanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annerose","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"2143_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","volume":"103","author":"AJ Camm","year":"2017","unstructured":"Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E et al (2017) Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 103:307\u2013314","journal-title":"Heart"},{"key":"2143_CR2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"2143_CR3","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","volume":"49","author":"WJ Powers","year":"2018","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K et al (2018) 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke 49:e46\u2013e110","journal-title":"Stroke"},{"key":"2143_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2396987317699144","volume":"2","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Steiner T, Caso V, Wahlgren N (2017) Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13\u201315 November 2016. European Stroke Journal 2:95\u2013102","journal-title":"European Stroke Journal"},{"key":"2143_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11239-016-1431-7","volume":"43","author":"DJ Seiffge","year":"2017","unstructured":"Seiffge DJ, Traenka C, Polymeris A, Hert L, Fisch U, Peters N et al (2017) Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis 43:112\u2013116","journal-title":"J Thromb Thrombolysis"},{"key":"2143_CR6","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1161\/STROKEAHA.115.010148","volume":"46","author":"M Ebner","year":"2015","unstructured":"Ebner M, Peter A, Spencer C, Hartig F, Birschmann I, Kuhn J et al (2015) Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants. Stroke 46:2741\u20132747","journal-title":"Stroke"},{"key":"2143_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cca.2018.08.017","volume":"486","author":"J Kuhn","year":"2018","unstructured":"Kuhn J, Gripp T, Flieder T, Hammerschmidt A, Hendig D, Faust I et al (2018) Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays. Clin Chim Acta 486:347\u2013356","journal-title":"Clin Chim Acta"},{"key":"2143_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/ene.13582","volume":"25","author":"E Touze","year":"2018","unstructured":"Touze E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P et al (2018) Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Eur J Neurol 25:747\u2013752","journal-title":"Eur J Neurol"},{"key":"2143_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jth.13227","volume":"14","author":"JH Levy","year":"2016","unstructured":"Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623\u2013627","journal-title":"J Thromb Haemost"},{"key":"2143_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/jth.12308","volume":"11","author":"EM Hawes","year":"2013","unstructured":"Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM et al (2013) Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11:1493\u20131502","journal-title":"J Thromb Haemost"},{"key":"2143_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857\u2013872","journal-title":"Stat Med"},{"key":"2143_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1747-4949.2010.00560.x","volume":"6","author":"T Steiner","year":"2011","unstructured":"Steiner T, Freiberger A, Griebe M, Husing J, Ivandic B, Kollmar R et al (2011) International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages\u2013the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex\u2013study design and protocol. Int J Stroke 6:271\u2013277","journal-title":"Int J Stroke"},{"key":"2143_CR13","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","volume":"351","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351:h5527","journal-title":"BMJ"},{"key":"2143_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1309\/AJCPQ2NJD3PXFTUG","volume":"143","author":"Y Morishima","year":"2015","unstructured":"Morishima Y, Kamisato C (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143:241\u2013247","journal-title":"Am J Clin Pathol"},{"key":"2143_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1161\/STROKEAHA.117.017981","volume":"48","author":"M Ebner","year":"2017","unstructured":"Ebner M, Birschmann I, Peter A, H\u00e4rtig F, Spencer C, Kuhn J et al (2017) Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 48:2457\u20132463","journal-title":"Stroke"},{"key":"2143_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","volume":"21","author":"M Ebner","year":"2017","unstructured":"Ebner M, Birschmann I, Peter A, Spencer C, Hartig F, Kuhn J et al (2017) Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care 21:32","journal-title":"Crit Care"},{"key":"2143_CR17","doi-asserted-by":"publisher","first-page":"e009807","DOI":"10.1161\/JAHA.118.009807","volume":"7","author":"M Ebner","year":"2018","unstructured":"Ebner M, Birschmann I, Peter A, Hartig F, Spencer C, Kuhn J et al (2018) Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis. J Am Heart Assoc 7:e009807","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-020-02143-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T03:42:31Z","timestamp":1621482151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-020-02143-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02143-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"20 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F. H\u00e4rtig and M. Ebner received reimbursement for congress traveling from Bayer. I. Birschmann received speaker\u2019s honoraria from Aspen Germany, Bristol-Myers Squibb\/Pfizer, Siemens Healthcare, and CSL Behring, and reimbursement for congress traveling from aspen and Bristol-Myers Squibb, and performed contract research for Siemens Healthcare. Ingvild Birschmann is a member of the advisory board of LFB biomedicaments. U. Ziemann received grants from German Research Foundation, German Federal Ministry of Education and Research, European Research Council, Bristol-Myers Squibb, Janssen Pharmaceuticals, Servier, and Biogen Idec, and consulting honoraria from Pfizer, Bayer Vital, and CorTec (all outside of the present work). S. Poli received speaker\u2019s\/consulting honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb\/Pfizer, Daiichi Sankyo, and Werfen, reimbursement for congress traveling from Bayer, and Boehringer-Ingelheim, and research support from Bristol-Myers Squibb\/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, and Helena Laboratories (all outside of the present work). The other authors (A. Peter, S. H\u00f6rber, M. Sonnleitner, C. Spencer, P. Bombach, M.-I. Stefanou, J. Kuhn, and A. Mengel) report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}